Welcome to our dedicated page for Regenxbio news (Ticker: RGNX), a resource for investors and traders seeking the latest updates and insights on Regenxbio stock.
Regenxbio Inc (RGNX) is a clinical-stage biotechnology leader advancing novel AAV gene therapies through its proprietary NAV® technology platform. This page provides investors and stakeholders with centralized access to the company’s latest press releases, clinical trial updates, and strategic developments.
Track critical updates across Regenxbio’s pipeline, including progress on RGX-202 for Duchenne muscular dystrophy, RGX-121 for Hunter syndrome, and ABBV-RGX-314 for retinal diseases. Stay informed about regulatory milestones, manufacturing advancements, and partnership announcements with entities like AbbVie.
All content is sourced directly from Regenxbio’s official communications, ensuring accuracy and timeliness. Bookmark this page for streamlined access to essential updates on one-time gene therapies targeting rare genetic disorders.
REGENXBIO Inc. (Nasdaq: RGNX) announced it will receive an $80 million milestone payment from Novartis AG due to Zolgensma achieving $1 billion in net sales. This revenue is expected to be recognized in Q3 2020. Zolgensma, a transformative gene therapy for spinal muscular atrophy, has positively impacted over 700 patients. Since its FDA approval in May 2019, REGENXBIO has received over $140 million from related royalties and milestones.
REGENXBIO Inc. (Nasdaq: RGNX) announced an expansion of its RGX-121 program for Mucopolysaccharidosis Type II (MPS II), aiming to understand the disease's neurodegenerative effects better. RGX-121, a potential gene therapy, delivers the enzyme iduronate-2-sulfatase to the central nervous system. An ongoing Phase I/II trial has dosed six patients with no serious adverse events reported. Additionally, the FDA has cleared a new IND for a trial involving pediatric patients aged 5-18. A natural history study will explore neurocognitive development in young MPS II patients.
REGENXBIO Inc. (Nasdaq: RGNX), a clinical-stage biotechnology company, announced its participation in three upcoming virtual investor conferences. These include the SVB Leerink CybeRx Series on October 1, 2020, the Jefferies Virtual Gene Therapy/Editing Summit on October 2, 2020, and the Chardan Virtual 4th Annual Genetic Medicines Conference on October 6, 2020, featuring a fireside chat at 10:30 a.m. ET. Investors can access a live webcast and a 30-day archived replay on the company's website.
REGENXBIO Inc. (Nasdaq: RGNX) has announced the dosing of its first patient in the AAVIATE trial, a Phase II study evaluating the suprachoroidal delivery of RGX-314 for treating wet age-related macular degeneration (wet AMD). This trial marks a significant milestone as it is the first to assess this delivery method for gene therapy. Interim data is expected by the end of 2020. RGX-314 aims to serve as a one-time treatment targeting the VEGF pathway to inhibit leaky blood vessel growth, addressing a condition affecting millions.
REGENXBIO Inc. (Nasdaq: RGNX), a leader in gene therapy, announced its participation in two September investor conferences. The events will be held virtually, starting with Citi's 15th Annual BioPharma Virtual Conference on September 9, 2020, followed by the Morgan Stanley 18th Annual Global Healthcare Conference on September 15, 2020, including a fireside chat at 8:45 a.m. ET. Interested investors can access a live webcast on REGENXBIO's website, with a replay available for 30 days post-event.
REGENXBIO Inc. (Nasdaq: RGNX) announced the FDA's clearance of its Investigational New Drug (IND) application for RGX-314 to treat diabetic retinopathy (DR). This IND activation allows the company to commence a Phase II trial named ALTITUDE in the second half of 2020, targeting around 40 patients. The primary endpoint is to evaluate patient improvement in DR severity after 48 weeks. This advancement is significant as DR is a major cause of blindness, affecting approximately 8 million people in the U.S.
REGENXBIO Inc. (Nasdaq: RGNX) reported its Q2 2020 financial results, noting significant advancements in its gene therapy programs amid the COVID-19 pandemic. Key highlights include plans to launch a pivotal program for RGX-314 in treating wet AMD by year-end, and the completion of patient dosing for RGX-121 targeting MPS II. Revenues surged to $16.6 million, attributed mainly to increased royalties from Zolgensma sales. However, the company incurred a net loss of $33.8 million. Cash reserves stood at $339.2 million, expected to fund development into 2022.
On August 4, 2020, REGENXBIO announced positive updates for RGX-314, a potential one-time treatment for wet AMD, following the Phase I/IIa trial results. The data showed RGX-314 was well-tolerated in 42 patients, with a significant reduction in anti-VEGF injections—61% and 85% in Cohorts 4 and 5, respectively. The pivotal program for subretinal delivery is set to begin by year-end 2020. Additionally, a Phase II trial (AAVIATE) utilizing suprachoroidal delivery is expected to enroll patients in Q3 2020. Interim data from the AAVIATE trial will be reported by late 2020.
REGENXBIO Inc. (Nasdaq: RGNX), a biotechnology firm focused on gene therapy, will host a conference call on August 6, 2020, at 4:30 p.m. ET, to discuss its financial results for Q2 2020, ending June 30, 2020.
The call will provide insights into the company's operational highlights and financial performance. Investors can participate by calling (800) 708-4539 (domestic) or (800) 619-6396 (international), or by accessing a live or recorded webcast on the REGENXBIO website.
REGENXBIO (Nasdaq: RGNX) announced on July 8, 2020, the completion of dosing three patients in Cohort 2 of its Phase I/II study of RGX-121 for Mucopolysaccharidosis Type II (MPS II). The data reported shows RGX-121 to be well-tolerated with no serious adverse events. The company also provided initial data on RGX-111 for MPS I, showing positive biochemistry results and sustained cognitive development in a patient treated. Both RGX-121 and RGX-111 are designed to improve outcomes in patients with rare genetic disorders, and further data updates are expected later this year.
